Skip to main content
Top
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Hepatitis C | Research article

Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study

Authors: Juan Vaz, Berne Eriksson, Ulf Strömberg, David Buchebner, Patrik Midlöv

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

The incidence of cirrhosis for individuals in Sweden has previously been reported as stable/low among European countries. However, Swedish population-based studies are scarce and none of them included data from the most recent decade (2010–2019). We aimed to describe the incidence and aetiology of cirrhosis in the Halland region from 2011 to 2018, and to describe the severity and prevalence of liver-related complications and other primary comorbidities at the time of cirrhosis diagnosis.

Methods

We conducted a retrospective cohort study of all patients with cirrhosis in Halland, which has a population of 310,000 inhabitants. Medical records and histopathology registries were reviewed.

Results

A total of 598 patients with cirrhosis were identified. The age-standardised incidence was estimated at 23.2 per 100,000 person-years (95% CI 21.3–25.1), 30.5 (95% CI 27.5–33.8) for men and 16.4 (95% CI 14.3–18.7) for women. When stratified by age, the highest incidence rates were registered at age 60–69 years. Men had a higher incidence rate for most age groups when compared to women. The most common aetiology was alcohol (50.5%), followed by cryptogenic cirrhosis (14.5%), hepatitis C (13.4%), and non-alcoholic fatty liver disease (5.7%). Most patients had at least one liver-related complication at diagnosis (68%). The most common comorbidities at diagnosis were arterial hypertension (33%), type 2 diabetes (29%) and obesity (24%).

Conclusions

Based on previous Swedish studies, our results indicate that the incidence of cirrhosis in Sweden might be considerably higher than previously reported. It is uncertain if the incidence of cirrhosis has previously been underestimated or if an actual increment has occurred during the course of the most recent decade. The increased incidence rates of cirrhosis reported in Halland are multifactorial and most likely related to higher incidence rates among the elderly. Pre-obesity and obesity are common in cirrhosis and non-alcoholic fatty liver disease has become an important cause of cirrhosis in Halland.
Appendix
Available only for authorised users
Literature
1.
go back to reference Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–71.CrossRef Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–71.CrossRef
2.
go back to reference Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.CrossRef Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.CrossRef
3.
go back to reference Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N, Committee EHS. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69(3):718–35.CrossRef Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N, Committee EHS. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69(3):718–35.CrossRef
4.
go back to reference Gunnarsdottir SA, Olsson R, Olafsson S, Cariglia N, Westin J, Thjodleifsson B, Bjornsson E. Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes. Scand J Gastroenterol. 2009;44(8):984–93.CrossRef Gunnarsdottir SA, Olsson R, Olafsson S, Cariglia N, Westin J, Thjodleifsson B, Bjornsson E. Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes. Scand J Gastroenterol. 2009;44(8):984–93.CrossRef
5.
go back to reference Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in southern Sweden: a 10-year population-based study. Aliment Pharmacol Ther. 2016;43(12):1330–9.CrossRef Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in southern Sweden: a 10-year population-based study. Aliment Pharmacol Ther. 2016;43(12):1330–9.CrossRef
7.
go back to reference Andersson T, Ahlbom A, Carlsson S. Diabetes prevalence in Sweden at present and projections for year 2050. PLoS One. 2015;10(11):e0143084.CrossRef Andersson T, Ahlbom A, Carlsson S. Diabetes prevalence in Sweden at present and projections for year 2050. PLoS One. 2015;10(11):e0143084.CrossRef
8.
go back to reference Dam Fialla A, Schaffalitzky de Muckadell OB, Lassen T. A: incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2012;47(6):702–9.CrossRef Dam Fialla A, Schaffalitzky de Muckadell OB, Lassen T. A: incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2012;47(6):702–9.CrossRef
9.
go back to reference Haukeland JW, Lorgen I, Schreiner LT, Frigstad SO, Brandsaeter B, Bjoro K, Bang C, Raknerud N, Konopski Z. Incidence rates and causes of cirrhosis in a Norwegian population. Scand J Gastroenterol. 2007;42(12):1501–8.CrossRef Haukeland JW, Lorgen I, Schreiner LT, Frigstad SO, Brandsaeter B, Bjoro K, Bang C, Raknerud N, Konopski Z. Incidence rates and causes of cirrhosis in a Norwegian population. Scand J Gastroenterol. 2007;42(12):1501–8.CrossRef
10.
go back to reference Ratib S, West J, Crooks CJ, Fleming KM. Diagnosis of liver cirrhosis in England, a cohort study, 1998-2009: a comparison with cancer. Am J Gastroenterol. 2014;109(2):190–8.CrossRef Ratib S, West J, Crooks CJ, Fleming KM. Diagnosis of liver cirrhosis in England, a cohort study, 1998-2009: a comparison with cancer. Am J Gastroenterol. 2014;109(2):190–8.CrossRef
11.
go back to reference Huber A, Ebner L, Heverhagen JT, Christe A. State-of-the-art imaging of liver fibrosis and cirrhosis: a comprehensive review of current applications and future perspectives. Eur J Radiol Open. 2015;2:90–100.CrossRef Huber A, Ebner L, Heverhagen JT, Christe A. State-of-the-art imaging of liver fibrosis and cirrhosis: a comprehensive review of current applications and future perspectives. Eur J Radiol Open. 2015;2:90–100.CrossRef
12.
go back to reference Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894(i-xii):1–253. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894(i-xii):1–253.
13.
go back to reference de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43(1):167–76.CrossRef de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43(1):167–76.CrossRef
14.
go back to reference Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.CrossRef Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.CrossRef
15.
go back to reference McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–55.CrossRef McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–55.CrossRef
16.
go back to reference Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski MS, Torriani FJ, Dieterich DT, Thomas DL, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.CrossRef Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski MS, Torriani FJ, Dieterich DT, Thomas DL, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.CrossRef
17.
go back to reference Peng Y, Qi X, Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016;95(8):e2877.CrossRef Peng Y, Qi X, Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016;95(8):e2877.CrossRef
18.
go back to reference European Commission. Revision of the European Standard Population — Report of Eurostat's task force. ISBN 978–92–79-31094-2; 2013. European Commission. Revision of the European Standard Population — Report of Eurostat's task force. ISBN 978–92–79-31094-2; 2013.
19.
go back to reference Crocetti E, Dyba T, Martos C, Randi G, Rooney R, Bettio M. The need for a rapid and comprehensive adoption of the revised European standard population in cancer incidence comparisons. Eur J Cancer Prev. 2017;26(5):447–52.CrossRef Crocetti E, Dyba T, Martos C, Randi G, Rooney R, Bettio M. The need for a rapid and comprehensive adoption of the revised European standard population in cancer incidence comparisons. Eur J Cancer Prev. 2017;26(5):447–52.CrossRef
20.
go back to reference Trolldal B, Guttormsson U, Leifman H. Registered and unregistered alcohol in the counties of Sweden 2001-2016. Report 165. Centralförbundet för alkohol- och narkotikaupplysning; 2017. Trolldal B, Guttormsson U, Leifman H. Registered and unregistered alcohol in the counties of Sweden 2001-2016. Report 165. Centralförbundet för alkohol- och narkotikaupplysning; 2017.
21.
go back to reference Hagstrom H, Elfwen O, Hultcrantz R, Stal P. Steatohepatitis is not associated with an increased risk for fibrosis progression in nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2018;2018:1942648.CrossRef Hagstrom H, Elfwen O, Hultcrantz R, Stal P. Steatohepatitis is not associated with an increased risk for fibrosis progression in nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2018;2018:1942648.CrossRef
22.
go back to reference Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73.CrossRef Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73.CrossRef
23.
go back to reference Caldwell SH, Lee VD, Kleiner DE, Al-Osaimi AM, Argo CK, Northup PG, Berg CL. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8(4):346–52.CrossRef Caldwell SH, Lee VD, Kleiner DE, Al-Osaimi AM, Argo CK, Northup PG, Berg CL. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8(4):346–52.CrossRef
24.
go back to reference Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? J Hepatol. 2018;68(3):519–25.CrossRef Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? J Hepatol. 2018;68(3):519–25.CrossRef
25.
go back to reference Caldwell S, Marchesini G. Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name. J Hepatol. 2018;68(3):391–2.CrossRef Caldwell S, Marchesini G. Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name. J Hepatol. 2018;68(3):391–2.CrossRef
26.
go back to reference Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in southern Sweden: a population-based study. Scand J Gastroenterol. 2019;54(8):1027–32.CrossRef Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in southern Sweden: a population-based study. Scand J Gastroenterol. 2019;54(8):1027–32.CrossRef
27.
go back to reference Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, Richardson P, Davila JA, Kanwal F. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016;43(5):621–30.CrossRef Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, Richardson P, Davila JA, Kanwal F. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016;43(5):621–30.CrossRef
28.
go back to reference Guss D, Sherigar J, Mohanty SR. Missed diagnosis of liver cirrhosis leads to disparities in Care for Older Patients. Gastroenterology Res. 2018;11(5):333–9.CrossRef Guss D, Sherigar J, Mohanty SR. Missed diagnosis of liver cirrhosis leads to disparities in Care for Older Patients. Gastroenterology Res. 2018;11(5):333–9.CrossRef
Metadata
Title
Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study
Authors
Juan Vaz
Berne Eriksson
Ulf Strömberg
David Buchebner
Patrik Midlöv
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Hepatitis C
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01239-6

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.